PT1429800E - Vacina e sua utilização para tratamento de esclerose lateral amiotrófica - Google Patents
Vacina e sua utilização para tratamento de esclerose lateral amiotrófica Download PDFInfo
- Publication number
- PT1429800E PT1429800E PT02788511T PT02788511T PT1429800E PT 1429800 E PT1429800 E PT 1429800E PT 02788511 T PT02788511 T PT 02788511T PT 02788511 T PT02788511 T PT 02788511T PT 1429800 E PT1429800 E PT 1429800E
- Authority
- PT
- Portugal
- Prior art keywords
- cop
- vaccine
- lateral sclerosis
- amyotrophic lateral
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33613901P | 2001-12-06 | 2001-12-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1429800E true PT1429800E (pt) | 2009-04-27 |
Family
ID=23314742
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT02788511T PT1429800E (pt) | 2001-12-06 | 2002-12-05 | Vacina e sua utilização para tratamento de esclerose lateral amiotrófica |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US7351686B2 (pt) |
| EP (1) | EP1429800B1 (pt) |
| JP (1) | JP4542339B2 (pt) |
| KR (1) | KR20040081431A (pt) |
| CN (2) | CN102151330B (pt) |
| AT (1) | ATE422362T1 (pt) |
| AU (1) | AU2002353486B2 (pt) |
| CA (1) | CA2469092C (pt) |
| CY (1) | CY1109044T1 (pt) |
| DE (1) | DE60231131D1 (pt) |
| DK (1) | DK1429800T3 (pt) |
| ES (1) | ES2322566T3 (pt) |
| HK (1) | HK1067043A1 (pt) |
| HU (1) | HU228207B1 (pt) |
| IL (1) | IL160105A0 (pt) |
| IS (1) | IS2670B (pt) |
| MX (1) | MXPA04005537A (pt) |
| NO (1) | NO336231B1 (pt) |
| NZ (1) | NZ533356A (pt) |
| PL (1) | PL205469B1 (pt) |
| PT (1) | PT1429800E (pt) |
| RU (1) | RU2303996C2 (pt) |
| SI (1) | SI1429800T1 (pt) |
| WO (1) | WO2003047500A2 (pt) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7399740B2 (en) | 2001-06-28 | 2008-07-15 | Yeda Research And Development Co. Ltd. | Poly-Glu,Tyr for neuroprotective therapy |
| AU2004203772B2 (en) * | 2003-01-07 | 2009-07-16 | Yeda Research And Development Co. Ltd. | Eye-drop vaccine containing copolymer 1 for therapeutic immunization |
| AU2004288654B2 (en) | 2003-11-12 | 2009-12-03 | Yeda Research And Development Co. Ltd. | Vaccine and method for treatment of neurodegenerative diseases |
| EP1701730B1 (en) | 2003-12-09 | 2013-08-21 | Yeda Research And Development Co., Ltd. | Method and vaccine comprising copolymer 1 for treatment of psychiatric disorders |
| CA2558380A1 (en) * | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| WO2005112972A1 (en) * | 2004-05-07 | 2005-12-01 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| JP5241012B2 (ja) | 2005-07-15 | 2013-07-17 | ノバルティス アーゲー | Ｐａｍｐｓ、病原体関連分子パターン |
| CN100448481C (zh) * | 2006-06-22 | 2009-01-07 | 中国科学院遗传与发育生物学研究所 | xCT蛋白及其编码基因的新用途 |
| EP2195008A1 (en) | 2007-09-24 | 2010-06-16 | Hadasit Medical Research Services & Development Ltd. | Use of copolymer 1 for treatment of muscular dystrophy |
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8759302B2 (en) * | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| MX347871B (es) | 2010-10-11 | 2017-05-16 | Teva Pharmaceutical Ind Ltd * | Biomarcadores de citoquina como marcadores predictivos de respuesta clínica para acetato de glatirámero. |
| EP2699317B1 (en) | 2011-04-21 | 2016-08-10 | Mapi Pharma Limited | Random pentapolymer for treatment of autoimmune diseases |
| AU2012323345A1 (en) | 2011-10-10 | 2014-05-22 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| WO2013084236A1 (en) * | 2011-12-05 | 2013-06-13 | Ben-Gurion University Of The Negev Research And Development Authority | Diagnostic and therapeutic methods and their application in amyotrophic lateral sclerosis (als) |
| ES2819174T3 (es) * | 2012-03-26 | 2021-04-15 | Yeda Res & Dev | Marcadores celulares para el diagnóstico de la enfermedad de Alzheimer y para la progresión de la enfermedad de Alzheimer |
| US20150238582A1 (en) | 2012-09-10 | 2015-08-27 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Individualized immunomodulation therapy for neurodegenerative disorders, cns injury and age-related dementia |
| CA3050086A1 (en) | 2017-03-26 | 2018-10-04 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| US3849650A (en) | 1973-03-29 | 1974-11-19 | Picker Corp | Automatic x-ray inspection system |
| IL113812A (en) | 1994-05-24 | 2000-06-29 | Yeda Res & Dev | Copolymer-1 pharmaceutical compositions containing it and its use |
| SE505316C2 (sv) * | 1995-10-17 | 1997-08-04 | Kenneth G Haglid | Användning av proteinet S-100b för framställning av läkemedel för nervceller |
| US20030108528A1 (en) | 1998-05-19 | 2003-06-12 | Michal Eisenbach-Schwartz | Activated t-cells, nervous system-specific antigens and their uses |
| US20020072493A1 (en) | 1998-05-19 | 2002-06-13 | Yeda Research And Development Co. Ltd. | Activated T cells, nervous system-specific antigens and their uses |
| WO1999060021A2 (en) | 1998-05-19 | 1999-11-25 | Yeda Research And Development Co. Ltd. | Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system |
| EP1039929A1 (en) | 1998-07-21 | 2000-10-04 | YEDA RESEARCH AND DEVELOPMENT Co. Ltd. | Activated t-cells and their uses |
| WO2000005249A2 (en) | 1998-07-23 | 2000-02-03 | The President And Fellows Of Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| AU780188B2 (en) * | 2000-01-20 | 2005-03-03 | Yeda Research And Development Co. Ltd. | The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
| ATE314860T1 (de) * | 2000-06-07 | 2006-02-15 | Yeda Res & Dev | Verwendung des copolymer-1 peptids sowie von damit verwandten peptiden und polypeptiden und von damit behandelten t-zellen zur neuroprotektion vor glutamattoxizitaet |
| WO2002076503A1 (en) * | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| US7399740B2 (en) * | 2001-06-28 | 2008-07-15 | Yeda Research And Development Co. Ltd. | Poly-Glu,Tyr for neuroprotective therapy |
| US6835711B2 (en) * | 2001-06-28 | 2004-12-28 | Yeda Research And Development Co. Ltd. | Use of poly-Glu,Tyr for neuroprotective therapy |
-
2002
- 2002-12-05 IL IL16010502A patent/IL160105A0/xx unknown
- 2002-12-05 AU AU2002353486A patent/AU2002353486B2/en not_active Ceased
- 2002-12-05 WO PCT/IL2002/000979 patent/WO2003047500A2/en active Application Filing
- 2002-12-05 NZ NZ533356A patent/NZ533356A/en not_active IP Right Cessation
- 2002-12-05 MX MXPA04005537A patent/MXPA04005537A/es active IP Right Grant
- 2002-12-05 KR KR10-2004-7008780A patent/KR20040081431A/ko active Search and Examination
- 2002-12-05 HU HU0500039A patent/HU228207B1/hu not_active IP Right Cessation
- 2002-12-05 DK DK02788511T patent/DK1429800T3/da active
- 2002-12-05 ES ES02788511T patent/ES2322566T3/es not_active Expired - Lifetime
- 2002-12-05 CN CN201110056639.8A patent/CN102151330B/zh not_active Expired - Fee Related
- 2002-12-05 SI SI200230800T patent/SI1429800T1/sl unknown
- 2002-12-05 EP EP02788511A patent/EP1429800B1/en not_active Expired - Lifetime
- 2002-12-05 CA CA2469092A patent/CA2469092C/en not_active Expired - Fee Related
- 2002-12-05 CN CNA028277015A patent/CN1617736A/zh active Pending
- 2002-12-05 JP JP2003548761A patent/JP4542339B2/ja not_active Expired - Fee Related
- 2002-12-05 US US10/485,576 patent/US7351686B2/en not_active Expired - Lifetime
- 2002-12-05 RU RU2004120536/14A patent/RU2303996C2/ru not_active IP Right Cessation
- 2002-12-05 PT PT02788511T patent/PT1429800E/pt unknown
- 2002-12-05 AT AT02788511T patent/ATE422362T1/de active
- 2002-12-05 DE DE60231131T patent/DE60231131D1/de not_active Expired - Lifetime
- 2002-12-05 PL PL370070A patent/PL205469B1/pl unknown
-
2004
- 2004-06-03 IS IS7296A patent/IS2670B/is unknown
- 2004-07-05 NO NO20042833A patent/NO336231B1/no not_active IP Right Cessation
- 2004-12-16 HK HK04110020.9A patent/HK1067043A1/xx not_active IP Right Cessation
-
2009
- 2009-05-06 CY CY20091100485T patent/CY1109044T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1067043A1 (en) | Vaccine and use thereof for treatment of amyotrophic lateral sclerosis | |
| AU6185398A (en) | Charged lipids and uses for the same | |
| AU6762794A (en) | A coagulation factor viii formulation | |
| IL110045A (en) | Pharmaceutical compositions containing oligopeptides for combating AIDS and ARC and for immune stimulation and certain such novel oligopeptides | |
| MY129566A (en) | A hypoallergenic composition containing tolerogenic peptides inducing oral tolerance | |
| WO2002100390A3 (en) | Improved method of treating the syndrome of coronary heart disease risk factors in humans | |
| PL399138A1 (pl) | Peptyd tolerogenny, kompozycja farmaceutyczna zawierająca ten peptyd, peptyd lub kompozycja farmaceutyczna do podawania i zastosowanie peptydu tolerogennego | |
| CA2299361A1 (en) | Use of consensus interferon in combination with il-1 receptor antagonist for treatment of patients afflicted with multiple sclerosis | |
| ZA200209982B (en) | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotogotine. | |
| IL108285A0 (en) | Use of riluzole for the treatment of parkinson's disease and parkinsonian syndromes | |
| NZ516477A (en) | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders | |
| AU7242796A (en) | Leishmania antigens for use in the therapy and diagnosis of leishmaniasis | |
| MXPA02005563A (es) | Formulacion estable de interferon en solucion acuosa, metodo de preparacion y usos de la misma. | |
| PL368686A1 (en) | Novel aminobenzoephenones | |
| MXPA02011533A (es) | Nuevas formulaciones de alfa-2,4-disulfofenil-n-terc-butilnitrona. | |
| YU45103A (sh) | Upotreba sarp/1 za lečenje i prevenciju skleroderme | |
| NZ505538A (en) | A vaccine comprising immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide (PIM); and the use of PIM for inducing an immune response in a patient effective in the prevention or treatment of Th2-mediated diseases or disorders such as asthma | |
| CA2414586A1 (en) | Agent for therapeutic treatment of optic nerve diseases and the like | |
| WO2003026570A3 (en) | Reduced toxicity cisplatin formulations and methods for using the same |